Cowen & Co. Reiterates a Buy Rating on Medicines Co.

In a report released today, Chris Shibutani from Cowen & Co. reiterated a Buy rating on Medicines Co. (NASDAQ: MDCO), with a price target of $45. The company’s shares opened today at $38.

Shibutani commented:

“We expect detailed results from the ORION-1 Phase II trial for the PCSK9si at the.”

According to, Shibutani is a 4-star analyst with an average return of 14.3% and a 48.1% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, United Therapeutics, and Puma Biotechnology.

Currently, the analyst consensus on Medicines Co. is Strong Buy and the average price target is $47, representing a 23.7% upside.

In a report issued on October 5, J.P. Morgan also reiterated a Buy rating on the stock.

The company has a one year high of $43 and a one year low of $27.50. Currently, Medicines Co. has an average volume of 942.8K.

Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MDCO in relation to earlier this year.

The Medicines Co. is a biopharmaceutical company, which focuses on advancing the treatment of critical care patients through the delivery of medicines to the worldwide hospital marketplace. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria; Orbactiv for the treatment of acute bacterial skin and skin structure infections; Orbactiv for the treatment of acute bacterial skin and skin structure infections; PreveLeak, a mechanical vascular and surgical sealant; ready-to-use formulation of Argatroban for the treatment of thrombosis; and Recothrom, a human recombinant thrombin used as an aid to hemostasis, as well as acute care generic products for acute cardiovascular, surgery and perioperative care, and serious infectious diseases. Its development stage products include Cangrelor for the prevention of platelet activation and aggregation; IONSYS for the short-term management of acute postoperative pain; Raplixa, a dry powder topical formulation of fibrogen and thrombin; and RPX-602 for the treatment of bacterial infections. The company’s products under development also comprise ABP-700, an intravenous anesthetic agent for moderate or deep sedation and general anesthesia in patients undergoing diagnostic or therapeutic procedures; ALN-PCSsc for the treatment of hypercholesterolemia; Carbavance, an antibiotic agent for the treatment of hospitalized patients with bacterial infections; and MDCO-216, a novel biologic, is a complex of a phospholipid and recombinantly manufactured ApoA-1 Milano, a naturally occurring variant of ApoA-1, a protein found in human high-density lipoprotein. Medicines was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ.